Results 21 to 30 of about 6,539 (194)

Effect of Cabergoline Treatment on Disease Control in Acromegaly Patients. [PDF]

, 2022
The aim of this study was to evaluate the efficacy of cabergoline in normalizing plasma IGF-I levels in acromegaly patients with elevated IGF-I levels after surgery and/or SRL therapy. Acromegaly patients (n: 143) were evaluated retrospectively. Patients
Gul, Nurdan, Bilgic, Bilge, Uzum, Ayse Kubat, Hacisahinogullari, Hulya, Selcukbiricik, Özlem, Yalin, Gulsah Yenidunya, Aral, Ferihan, Tanakol, Refik   +7 more
core   +1 more source

Long-term Effects of Cabergoline and Levodopa in Japanese Patients with Early Parkinson’s Disease: A 5-Year Prospective Study [PDF]

, 2012
Several international studies have suggested that treatment of early Parkinsonʼs disease (PD) with a dopamine agonist instead of levodopa delays the occurrence of motor complications.
Utsumi, Hiroya, Cabergoline as the Starting Treatment and its Long-term Effects (CASTLE) Study Group,   +1 more
core   +1 more source

Low-Dose Tadalafil and Cabergoline versus Cabergoline alone in Management of Erectile Dysfunction in Patients with End-Stage Renal Disease and Hyperprolactinemia Undergoing Hemodialysis [PDF]

Al-Azhar International Medical Journal
Background: Hyperprolactinemia in chronic kidney disease (CKD) is associated with high rates of hypogonadism and erectile dysfunction (ED). This study compares the efficacy, safety, and side effects of cabergoline monotherapy versus low-dose tadalafil ...
Elsayed Salih, Ali Abd ElMaqsood, Mohammed Elsalhy, Hazem Ayoub   +3 more
doaj   +1 more source

Therapeutic activity of sarpogrelate and dopamine D2 receptor agonists on cardiovascular and renal systems in rats with alloxan-induced diabetes

BMC Pharmacology and Toxicology, 2021
Background Dopamine D2 receptor agonists, bromocriptine and cabergoline, are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia.
Mohammed Ahmed Fouad Shalaby, Hekma A. Abd El Latif, Mohamed El Yamani, May Ahmed Galal, Sherifa Kamal, Ikhlas Sindi, Raneem Masaood   +6 more
doaj   +1 more source

Diabetes mellitus remission in a cat with hyperadrenocorticism after cabergoline treatment

Journal of Feline Medicine and Surgery Open Reports, 2021
Case summary A 7-year-old spayed female domestic shorthair cat weighing 5 kg was referred with polyuria, polydipsia, lethargy, abdominal distension and dermatologic abnormalities.
Diego D Miceli, Gabriela S Zelarayán, Jorge D García, Viviana Fernández, Sergio Ferraris   +4 more
doaj   +1 more source

Preventing ovarian hyperstimulation syndrome: cabergoline versus coasting [PDF]

, 2013
The use of cabergoline and coasting are both effective in reducing the risk of ovarian hyperstimulation syndrome (OHSS).
BOZDAĞ, GÜRKAN, Karakocsokmensuer, Lale, ESİNLER, İBRAHİM   +2 more
core   +1 more source

A Practical Synthesis of Cabergoline [PDF]

The Journal of Organic Chemistry, 2002
Cabergoline is an N-acylurea derived from 9,10-dihydrolysergic acid, which is a potent prolactin inhibitor. It is marketed by Pharmacia as Dostinex for the treatment of hyperprolactinemia and is currently under active development for the treatment of a variety of CNS disorders.
Scott W, Ashford, Kevin E, Henegar, Andrew M, Anderson, Peter G M, Wuts   +3 more
openaire   +2 more sources

Cabergoline and the risk of valvular lesions in endocrine disease. [PDF]

, 2008
peer reviewedAIMS: The cardiac valvular risk associated with lower exposure to cabergoline in common endocrine conditions such as hyperprolactinemia is unknown.
Livadariu, E., Betea, Daniela, Pierard, Luc, Markov, M., Burlacu, M. C., Lancellotti, Patrizio, Daly, Adrian, Beckers, Albert   +7 more
core   +1 more source

Cabergoline for Cushing's disease: a large retrospective multicenter study. [PDF]

, 2017
peer reviewedOBJECTIVE: The efficacy of cabergoline in Cushing's disease (CD) is controversial. The aim of this study was to assess the efficacy and tolerability of cabergoline in a large contemporary cohort of patients with CD.
Chabre, Olivier, Cortet, Chrisitine, Delemer, B., Maiter, D., Briet, C., Beckers, Albert, Cephise-Velayoudom, F. L., Tabarin, Antoine, Maiter, Dominique, Castinetti, Frédéric, Chanson, Philippe, Castinetti, F., Haissaguerre, M., Briet, Claire, Caron, Philippe, Ferriere, Amandine, Delemer, Brigitte, Nunes, M. L., Raingeard, I., Bertherat, Jérôme, Cephise-Velayoudom, Fritz Line, Haissaguerre, Magalie, Caron, P., Reznik, Yves, Rohmer, Vincent, Chabre, O., Nunes, Marie Laure, Chanson, P., Cortet, C., Rohmer, V., Tabarin, A., VROONEN, Laurent, Ferriere, A., Reznik, Y., Raingeard, Isabelle, Bertherat, J.   +35 more
core   +1 more source

Cabergoline induced upregulation of glutamate transporters. [PDF]

, 2014
(A) Pretreatment with cabergoline reduced H2O2-induced extracellular glutamate accumulation. Pretreatment with cabergoline was performed 24 hours before H2O2 application.
Naoki Adachi (575911), Takafumi Inoue (575915), Yoshiko Ooshima (575912), Haruki Odaka (575909), Yusuke Katanuma (575914), Hiroshi Kunugi (276981), Tadahiro Numakawa (575910), Shingo Nakajima (575913)   +7 more
core   +1 more source